Haemonetics Corporation (HAE)
Stock Price Chart
Key Info
| Market Cap | 4.75B |
| Revenue (ttm) | 945.61M |
| Net Income (ttm) | 95.53M |
| Shares Out | 50.70M |
| EPS (ttm) | 1.85 |
| PE Ratio | 50.69 |
| Forward PE | 33.78 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 16, 2020 |
| Last Price | $93.78 |
| Previous Close | $95.34 |
| Change ($) | -1.56 |
| Change (%) | -1.64% |
| Day's Open | 95.43 |
| Day's Range | 93.14 - 96.58 |
| Day's Volume | 341,216 |
| 52-Week Range | 63.41 - 130.75 |
More Stats
| Market Cap | 4.75B |
| Enterprise Value | 5.01B |
| Earnings Date (est) | Nov 4, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 50.70M |
| Float | 50.13M |
| EPS (basic) | 1.89 |
| EPS (diluted) | 1.85 |
| FCF / Share | 2.70 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 1.97% |
| FCF Yield | 2.86% |
| Payout Ratio | n/a |
| Shares Short | 981,751 |
| Short Ratio | 2.34 |
| Short % of Float | 1.96% |
| Beta | 0.56 |
| PE Ratio | 50.69 |
| Forward PE | 33.78 |
| P/FCF Ratio | 34.94 |
| PS Ratio | 5.03 |
| PB Ratio | 7.94 |
| Revenue | 945.61M |
| Operating Income | 128.37M |
| Net Income | 95.53M |
| Free Cash Flow | 136.07M |
| Net Cash | -252.53M |
| Net Cash / Share | -4.98 |
| Gross Margin | 51.59% |
| Operating Margin | 13.58% |
| Profit Margin | 10.10% |
| FCF Margin | 14.39% |
| ROA | 7.02% |
| ROE | 15.93% |
| ROIC | 14.20% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2017 | 2016 | 2014 | 2013 | 2012 | 2011 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 988 | 968 | 904 | 886 | 909 | 910 | 939 | 892 | 728 | 677 |
| Revenue Growth | 2.16% | 7.04% | 2.01% | -2.5% | -0.17% | -3% | 5.22% | 22.55% | 7.56% | - |
| Gross Profit | 485 | 418 | 412 | 378 | 406 | 434 | 468 | 428 | 369 | 355 |
| Operating Income | 103 | 83.55 | 56.16 | -19.38 | -43.94 | 40.54 | 46.43 | 56.44 | 88.76 | 111 |
| Net Income | 76.53 | 55.02 | 45.57 | -26.27 | -55.58 | 16.90 | 35.15 | 38.80 | 66.89 | 79.98 |
| Shares Outstanding | 50.69 | 51.53 | 52.76 | 51.52 | 50.91 | 51.53 | 51.61 | 51.35 | 50.73 | 50.15 |
| Earnings Per Share | 1.48 | 1.04 | 0.85 | -0.51 | -1.09 | 0.32 | 0.67 | 0.74 | 1.30 | 1.56 |
| EPS Growth | 42.31% | 22.35% | - | - | - | -52.24% | -9.46% | -43.08% | -16.67% | - |
| Operating Cash Flow | 158 | 159 | 220 | 160 | 122 | 127 | 140 | 85.07 | 115 | 123 |
| Capital Expenditures | -31.98 | -116 | -72.04 | -73.31 | -102 | -122 | -73.16 | -60.22 | -52.20 | -45.20 |
| Free Cash Flow | 126 | 43.13 | 148 | 86.43 | 20.10 | 5.41 | 66.36 | 24.85 | 63.12 | 78.25 |
| Cash & Equivalents | 137 | 169 | 180 | 140 | 115 | 161 | 192 | 179 | 229 | 197 |
| Total Debt | 382 | 350 | 254 | 315 | 408 | 428 | 438 | 480 | 3.77 | 4.88 |
| Net Cash / Debt | -245 | -181 | -73.51 | -175 | -293 | -267 | -245 | -301 | 225 | 192 |
| Assets | 1,267 | 1,275 | 1,237 | 1,239 | 1,319 | 1,485 | 1,514 | 1,462 | 911 | 833 |
| Liabilities | 680 | 607 | 485 | 499 | 598 | 659 | 676 | 693 | 179 | 147 |
| Book Value | 587 | 668 | 752 | 740 | 722 | 826 | 838 | 769 | 733 | 686 |
Company Profile
Company Details
| Full Name | Haemonetics Corporation |
| Country | United States |
| Employees | 3,004 |
| CEO | Christopher A. Simon |
Stock Information
| Ticker Symbol | HAE |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Unique Identifier | NYSE: HAE |
| IPO Date | May 9, 1991 |
Description
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.